Skip to main content
SpringerLink
Log in

Serum Growth Arrest-Specific Protein 6 Levels are a Reliable Biomarker of Disease Activity in Systemic Lupus Erythematosus

  • Original Research
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Purpose

Growth arrest-specific protein 6 (Gas6) has been suggested to be a biomarker of disease activity in patients with systemic lupus erthematosus (SLE). We investigated the clinical significance of this protein in Korean SLE.

Methods

Blood samples were collected from 150 SLE patients and 50 normal controls (NC). In addition, follow-up samples were collected from 50 SLE patients.

Results

Serum Gas6 levels of SLE patients (43.01 ± 28.02 ng/mL) were higher than those of NC (20.15 ± 9.23 ng/mL, p < 0.001). When evaluated sensitivity and specificity of the Gas6 for diagnosing SLE using ROC curves, the sensitivity and specificity were 72.7 % and 84 % with a cut-off value of 25.3 ng/mL. In the ROC analysis of Gas6, anti-dsDNA antibody, ESR, complement 3 and complement 4 to identify patients with active lupus, area under the curve (AUC) of Gas6 was highest with 0.763. Serum Gas6 levels were significantly higher in the patients with serositis (70.04 ± 30.85 ng/mL) and renal disorder (65.66 ±32.28 ng/mL) compared to those without (41.88 ± 27.44 ng/mL, p = 0.033, 40.3 ± 26.33 ng/mL, p = 0.001, respectively). Gas6 levels were correlated positively with anti-dsDNA antibody (r = 0.199, p = 0.015), ESR (r = 0.204, p = 0.013) and SLEDAI (r = 0.512, p < 0.001). In addition, serum Gas6 levels were correlated negatively with hemoglobin (r = −0.165, p = 0.043), lymphocyte count (r = −0.165, p = 0.043), complement 3 (r = −0.343, p < 0.001) and complement 4 (r = −0.316, p < 0.001). Furthermore, change in serum Gas6 levels was correlated with change in SLEDAI levels in the SLE patients that were followed up (r = 0.524, p < 0.001).

Conclusion

These results suggest that serum Gas6 can be a reliable clinical marker for monitoring disease activity and treatment response in SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

ACR:

American College of Rheumatology

anti-dsDNA:

Anti-double stranded DNA

BILAG:

British Isles Lupus Assessment Group

ESR:

Erythrocyte sedimentation rate

Gas6:

Growth arrest-specific protein 6

NC:

Normal controls

SLE:

Systemic lupus erthematosus

SLEDAI:

Systemic lupus erythematosus disease activity index

TBST:

0.1 % Tween 20 in TBS

TAM:

Tyro-3, Axl and Mer

References

  1. Kotzin BL. Systemic lupus erythematosus. Cell. 1996;85:303–6.

    Article  PubMed  CAS  Google Scholar 

  2. Pisetsky DS. Anti-DNA and autoantibodies. Curr Opin Rheumatol. 2000;12:364–8.

    Article  PubMed  CAS  Google Scholar 

  3. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989;32:1107–18.

    Article  PubMed  CAS  Google Scholar 

  4. Merrill JT, Erkan D, Buyon JP. Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov. 2004;3:1036–46.

    Article  PubMed  CAS  Google Scholar 

  5. Petri M. Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis. 2007;66 Suppl 3:iii61–4.

    Article  PubMed  Google Scholar 

  6. Suh CH, Kim HA. Cytokines and their receptors as biomarkers of systemic lupus erythematosus. Expert Rev Mol Diagn. 2008;8:189–98.

    Article  PubMed  CAS  Google Scholar 

  7. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 2004;50:2048–65.

    Article  PubMed  CAS  Google Scholar 

  8. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol. 1993;13:4976–85.

    PubMed  CAS  Google Scholar 

  9. Hafizi S, Dahlback B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 2006;273:5231–44.

    Article  PubMed  CAS  Google Scholar 

  10. Godowski PJ, Mark MR, Chen J, Sadick MD, Raab H, Hammonds RG. Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell. 1995;82:355–8.

    Article  PubMed  CAS  Google Scholar 

  11. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem. 1996;271:30022–7.

    Article  PubMed  CAS  Google Scholar 

  12. Bellosta P, Zhang Q, Goff SP, Basilico C. Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene. 1997;15:2387–97.

    Article  PubMed  CAS  Google Scholar 

  13. Tjwa M, Bellido-Martin L, Lin Y, Lutgens E, Plaisance S, Bono F, et al. Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes. Blood. 2008;111:4096–105.

    Article  PubMed  CAS  Google Scholar 

  14. Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. Cell. 2010;140:619–30.

    Article  PubMed  CAS  Google Scholar 

  15. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science. 2001;293:306–11.

    Article  PubMed  CAS  Google Scholar 

  16. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med. 2002;196:135–40.

    Article  PubMed  CAS  Google Scholar 

  17. Yanagita M, Ishimoto Y, Arai H, Nagai K, Ito T, Nakano T, et al. Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. J Clin Invest. 2002;110:239–46.

    PubMed  CAS  Google Scholar 

  18. Yanagita M, Arai H, Ishii K, Nakano T, Ohashi K, Mizuno K, et al. Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis. Am J Pathol. 2001;158:1423–32.

    Article  PubMed  CAS  Google Scholar 

  19. Suh CH, Hilliard B, Li S, Merrill JT, Cohen PL. TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:R146.

    Article  PubMed  Google Scholar 

  20. Ekman C, Jonsen A, Sturfelt G, Bengtsson AA, Dahlback B. Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2011;50:1064–9.

    Article  CAS  Google Scholar 

  21. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B, et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res. 2009;15:4742–9.

    Article  PubMed  CAS  Google Scholar 

  22. Balogh I, Hafizi S, Stenhoff J, Hansson K, Dahlback B. Analysis of Gas6 in human platelets and plasma. Arterioscler Thromb Vasc Biol. 2005;25:1280–6.

    Article  PubMed  CAS  Google Scholar 

  23. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35–83.

    Article  PubMed  CAS  Google Scholar 

  24. Fernandez-Fernandez L, Bellido-Martin L, Garcia de Frutos P. Growth arrest-specific gene 6 (GAS6). An outline of its role in haemostasis and inflammation. Thromb Haemost. 2008;100:604–10.

    PubMed  CAS  Google Scholar 

  25. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature. 2001;411:207–11.

    Article  PubMed  CAS  Google Scholar 

  26. Uehara S, Handa H, Gotoh K, Tomita H, Sennshuu M. Plasma concentrations of growth arrest-specific protein 6 and protein S in patients with acute pancreatitis. J Gastroenterol Hepatol. 2009;24:1567–73.

    Article  PubMed  CAS  Google Scholar 

  27. Gibot S, Massin F, Cravoisy A, Dupays R, Barraud D, Nace L, et al. Growth arrest-specific protein 6 plasma concentrations during septic shock. Crit Care. 2007;11:R8.

    Article  PubMed  Google Scholar 

  28. Borgel D, Clauser S, Bornstain C, Bieche I, Bissery A, Remones V, et al. Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. Crit Care Med. 2006;34:219–22.

    Article  PubMed  CAS  Google Scholar 

  29. O’Donnell K, Harkes IC, Dougherty L, Wicks IP. Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway. Am J Pathol. 1999;154:1171–80.

    Article  PubMed  Google Scholar 

  30. Sainaghi PP, Collimedaglia L, Alciato F, Leone MA, Puta E, Naldi P, et al. Elevation of Gas6 protein concentration in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy (CIDP). J Neurol Sci. 2008;269:138–42.

    Article  PubMed  CAS  Google Scholar 

  31. Chen C, Li Q, Darrow AL, Wang Y, Derian CK, Yang J, et al. Mer receptor tyrosine kinase signaling participates in platelet function. Arterioscler Thromb Vasc Biol. 2004;24:1118–23.

    Article  PubMed  CAS  Google Scholar 

  32. Ekman C, Site DF, Gottsater A, Lindblad B, Dahlback B. Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms. Clin Biochem. 2010;43:110–4.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Rheumatology and BK21 Division of Cell Transformation and Restoration, Ajou University School of Medicine, San 5, Wonchon-dong, Yeongtong-gu, Suwon, South Korea, 443-721

    Hyoun-Ah Kim, Jin-Young Nam, Ja-Young Jeon, Jeong-Mi An, Ju-Yang Jung, Chang-Bum Bae & Chang-Hee Suh

Authors
  1. Hyoun-Ah Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin-Young Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ja-Young Jeon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeong-Mi An
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ju-Yang Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chang-Bum Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chang-Hee Suh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chang-Hee Suh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, HA., Nam, JY., Jeon, JY. et al. Serum Growth Arrest-Specific Protein 6 Levels are a Reliable Biomarker of Disease Activity in Systemic Lupus Erythematosus. J Clin Immunol 33, 143–150 (2013). https://doi.org/10.1007/s10875-012-9765-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-012-9765-1

Keywords

Search

Navigation